Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting
Actinium Pharmaceuticals (NYSE: ATNM) announced the acceptance of two abstracts for presentation at the AACR 2023 Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on the novel application of Actimab-A to deplete immunosuppressive myeloid-derived suppressor cells (MDSCs) and the effectiveness of HER3-targeting radiotherapy in solid tumors, showcasing potent anti-cancer activity. Actinium's Chairman, Sandesh Seth, emphasized the company's commitment to advancing targeted radiotherapies to address significant medical needs, supported by their recent CRADA with the NCI for developing Actimab-A in various clinical trials.
- Acceptance of two abstracts at AACR 2023 highlights significant advancements in targeted radiotherapies.
- Actimab-A shows promise in depleting immunosuppressive MDSCs, potentially enhancing anti-tumor immunity.
- HER3-targeting radiotherapy demonstrates potent efficacy in ovarian and colorectal cancer models.
- None.
- First ever data demonstrating the novel application of Actimab-A to enhance antitumor immune activity by depleting MDSCs, a population of highly immunosuppressive cells closely associated with poor clinical outcomes in cancer
- New solid tumor program data including the first exploration of the effects of targeting HER3 with either alpha (225Ac)- or beta (177Lu)- emitting radiotherapeutics in ovarian and colorectal cancer models, demonstrating potent anti-cancer activity
Accepted presentations will feature data that continue to support potent anti-tumor activity of Actinium's first-in-class HER3 radiotherapy in preclinical models of cancers with unmet therapeutic needs, as well as new data evaluating novel applications of Actimab-A to selectively deplete CD33+ myeloid-derived suppressor cells (MDSCs), a highly immunosuppressive cell type that is a major component of the tumor microenvironment.
"Actinium is applying our significant experience in developing and advancing clinical-stage targeted radiotherapeutics to further bolster our R&D leadership position in the field. We are excited to highlight new data from our HER3 targeting radiotherapy program as well as our novel strategy utilizing Actimab-A to deplete MDSCs, reactivating T cell responses in the tumor microenvironment at this year's AACR annual meeting.", said
The abstracts are available on AACR's website. Actinium's presentation details are as follows:
Abstract Title: Targeting myeloid-derived suppressor cells with actinium-225 lintuzumab, a CD33 antibody radioconjugate to enhance antitumor immunity
Session Category: Clinical Research Excluding Trials
Session Title: Immunomodulatory Agents and Interventions
Session Date and Time:
Location: Poster Section 40
Poster Board Number: 7
Published Abstract Number: 4421
Abstract Title: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Theranostics and Radionuclides / Pharmacologic Approaches
Session Date and Time:
Location: Section 19
Poster Board Number: 7
Abstract Presentation Number: 5040
About
Investors:
Hans Vitzthum
Hans@LifeSciAdvisors.com
(617) 430-7578
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-to-showcase-first-in-class-targeted-radiotherapies-in-two-presentations-at-the-2023-aacr-annual-meeting-301773721.html
SOURCE
FAQ
What are the key findings of Actinium's recent press release regarding Actimab-A?
When will Actinium present at the AACR 2023 Annual Meeting?
What is the significance of Actinium's CRADA with the NCI?